iBio, Inc. Files 8-K: Material Agreement & Disclosures

Ticker: IBIO · Form: 8-K · Filed: 2025-08-21T00:00:00.000Z

Sentiment: neutral

Topics: material-agreement, disclosure, financials

TL;DR

iBio signed a big deal, filed financials, and dropped some news. Keep an eye on this one.

AI Summary

On August 19, 2025, iBio, Inc. entered into a material definitive agreement, the details of which are not fully disclosed in this filing. The company also made a Regulation FD disclosure and filed financial statements and exhibits. iBio, Inc. is incorporated in Delaware and its principal executive offices are located in San Diego, California.

Why It Matters

This 8-K filing indicates a significant event for iBio, Inc., potentially involving a new material agreement that could impact its business operations and financial standing.

Risk Assessment

Risk Level: medium — The filing indicates a material definitive agreement, which could represent significant opportunities or risks for the company, but the lack of specific details warrants a medium risk assessment.

Key Players & Entities

FAQ

What is the nature of the material definitive agreement entered into by iBio, Inc. on August 19, 2025?

The filing states that iBio, Inc. entered into a material definitive agreement on August 19, 2025, but the specific terms and nature of this agreement are not detailed in the provided text.

What other items are reported in this 8-K filing besides the material definitive agreement?

This 8-K filing also includes a Regulation FD Disclosure and Financial Statements and Exhibits.

Where are iBio, Inc.'s principal executive offices located?

iBio, Inc.'s principal executive offices are located at 11750 Sorrento Valley Road, Suite 200, San Diego, California 92121.

In which state is iBio, Inc. incorporated?

iBio, Inc. is incorporated in Delaware.

What is the Commission File Number for iBio, Inc.?

The Commission File Number for iBio, Inc. is 001-35023.

From the Filing

0001104659-25-081419.txt : 20250821 0001104659-25-081419.hdr.sgml : 20250821 20250821161141 ACCESSION NUMBER: 0001104659-25-081419 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 21 CONFORMED PERIOD OF REPORT: 20250819 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250821 DATE AS OF CHANGE: 20250821 FILER: COMPANY DATA: COMPANY CONFORMED NAME: iBio, Inc. CENTRAL INDEX KEY: 0001420720 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 262797813 STATE OF INCORPORATION: DE FISCAL YEAR END: 0630 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35023 FILM NUMBER: 251240889 BUSINESS ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 BUSINESS PHONE: 302 355-0650 MAIL ADDRESS: STREET 1: 600 MADISON AVENUE, SUITE 1601 CITY: NEW YORK STATE: NY ZIP: 10022-1737 FORMER COMPANY: FORMER CONFORMED NAME: iBioPharma, Inc. DATE OF NAME CHANGE: 20080806 FORMER COMPANY: FORMER CONFORMED NAME: InB:Biotechnologies, Inc. DATE OF NAME CHANGE: 20071210 8-K 1 tm2523907d1_8k.htm FORM 8-K false 0001420720 0001420720 2025-08-19 2025-08-19 iso4217:USD xbrli:shares iso4217:USD xbrli:shares       UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549   FORM 8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (date of earliest event reported): August 19, 2025   iBio, Inc. (Exact name of registrant as specified in charter)   Delaware (State or other jurisdiction of incorporation)   001-35023 26-2797813 (Commission File Number) (IRS Employer Identification No.)   11750 Sorrento Valley Road , Suite 200 San Diego , California 92121 (Address of principal executive offices and zip code)   ( 979 ) 446-0027 (Registrant’s telephone number including area code)   N/A (Former Name and Former Address)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of registrant under any of the following provisions:     ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)     ¨ Soliciting material pursuant to Rule 14a-12(b) under the Exchange Act (17 CFR 240.14a-12)     ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))     ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, $0.001 par value per share IBIO The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company   ¨   If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ¨             Item 1.01. Entry Into a Material Definitive Agreement.    On August  19, 2025, iBio, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, as representative of the underwriters named in Schedule A thereto, relating to the offering, issuance and sale of pre-funded warrants (the “Pre-Funded Warrants”) to purcha

View on Read The Filing